Published in Am J Health Syst Pharm on June 15, 2008
Analysis of cost avoidance from pharmacy students' clinical interventions at a psychiatric hospital. Am J Pharm Educ (2011) 1.07
Realizing the pharmacoeconomic benefit of clinical pharmacy. Am J Health Syst Pharm (2008) 1.00
Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection (2016) 0.97
Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res (2014) 0.93
Prescription, Dispensation, and Generic Medicine Replacement Ratios: Influence on Japanese Medicine Costs. Glob J Health Sci (2015) 0.92
Should Pharmacy Technicians Provide Clinical Services or Perform Patient Care Activities in Areas without a Pharmacist? Can J Hosp Pharm (2010) 0.92
Medication reviews for nursing home residents to reduce mortality and hospitalization: systematic review and meta-analysis. Br J Clin Pharmacol (2014) 0.90
Analysis of clinical interventions and the impact of pediatric pharmacists on medication error prevention in a teaching hospital. J Pediatr Pharmacol Ther (2012) 0.89
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital. BMJ Open (2013) 0.83
A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open (2012) 0.81
Factors affecting the cost effectiveness of antibiotics. Chemother Res Pract (2011) 0.80
Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study. Daru (2015) 0.78
Transparent and reproducible reports of economic evaluations of clinical pharmacy services: a goal for the future? Am J Health Syst Pharm (2009) 0.78
Effect of a resident physician educational program on pediatric emergency department pharmacy interventions and medication errors. J Pediatr Pharmacol Ther (2013) 0.78
Physicians as executives: opportunities and strategies for health-system pharmacy leaders. Hosp Pharm (2014) 0.75
Japanese Community Pharmacists' Dispensing Influences Medicine Price Reduction more than Prescription Numbers. Glob J Health Sci (2015) 0.75
Pharmacists' Research Contributions in the Fight against HIV/AIDs. AIDS Res Treat (2012) 0.75
Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study. BMC Health Serv Res (2011) 0.75
Impact of clinical pharmacist in an Indian Intensive Care Unit. Indian J Crit Care Med (2016) 0.75
Guidelines recommendations on care of adult patients receiving home parenteral nutrition: a systematic review of global practices. Clin Nutr (2012) 2.08
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis (2012) 2.00
Pharmacist- versus physician-acquired medication history: a prospective study at the emergency department. Qual Saf Health Care (2010) 1.77
A comparative study of European rare disease and orphan drug markets. Health Policy (2010) 1.73
Impact, regulation and health policy implications of physician migration in OECD countries. Hum Resour Health (2004) 1.72
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ (2010) 1.59
Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm (2011) 1.45
Increasing nurse staffing levels in Belgian cardiac surgery centres: a cost-effective patient safety intervention? J Adv Nurs (2010) 1.42
Generic medicine pricing in Europe: current issues and future perspective. J Med Econ (2008) 1.32
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy (2011) 1.29
International trends in lifelong learning for pharmacists. Am J Pharm Educ (2007) 1.27
A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy (2009) 1.18
Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy (2011) 1.10
The costs of breast cancer prior to and following diagnosis. Eur J Health Econ (2010) 1.09
Critical assessment of belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics (2011) 1.09
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis (2013) 1.08
Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother (2009) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother (2007) 1.05
Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med (2009) 1.03
Epidemiology of catheter-related infections in adult patients receiving home parenteral nutrition: a systematic review. Clin Nutr (2012) 1.02
A simple tool to improve medication reconciliation at the emergency department. Eur J Intern Med (2011) 1.00
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy (2013) 1.00
Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy (2008) 0.99
Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res (2013) 0.97
The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics (2011) 0.96
Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis (2014) 0.96
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy (2010) 0.94
The impact of informing psychiatric patients about their medication: a systematic review. Pharm World Sci (2007) 0.94
Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother (2008) 0.93
Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC Health Serv Res (2014) 0.93
Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother (2012) 0.92
The impact of a transjugular intrahepatic portosystemic shunt on the pharmacokinetics of caspofungin in a critically ill patient. Pharmacology (2012) 0.92
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract (Granada) (2012) 0.90
Clinical evidence for orphan medicinal products-a cause for concern? Orphanet J Rare Dis (2013) 0.90
Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial. Crit Care (2012) 0.89
Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics (2014) 0.88
Economic evaluations of homeopathy: a review. Eur J Health Econ (2013) 0.87
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res (2014) 0.87
Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy (2013) 0.87
European drug shortages: a call for action! Int J Pharm Pract (2013) 0.87
Evaluation of drotrecogin alpha use in a Belgian university hospital. Pharm World Sci (2006) 0.87
Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis (2014) 0.86
Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion. Int Immunopharmacol (2011) 0.86
Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia. Scand J Infect Dis (2012) 0.86
Market access of cancer drugs in European countries: improving resource allocation. Target Oncol (2013) 0.85
Evaluating and improving orphan drug regulations in Europe: a Delphi policy study. Health Policy (2012) 0.84
Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res (2013) 0.84
Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J Antimicrob Chemother (2009) 0.84
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med (2014) 0.83
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
[Orphan diseases and orphan medicines: a Belgian and European study]. J Pharm Belg (2009) 0.82
Valorising and creating access to innovative medicines in the European union. Front Pharmacol (2011) 0.81
Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother (2011) 0.81
The Eagle-like effect of echinocandins: what's in a name? Expert Rev Anti Infect Ther (2013) 0.81
Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone (2008) 0.79
Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis. Eur J Clin Pharmacol (2011) 0.79
Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange. Ther Drug Monit (2013) 0.78
Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med (2010) 0.78
No interference of the 1,3-β-D-glucan containing nutritional supplement ImunixX with the 1,3-β-D-glucan serum test. Mycoses (2010) 0.77
Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus. Am J Health Syst Pharm (2007) 0.77
Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool. Orphanet J Rare Dis (2013) 0.77
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin (2008) 0.77
Implementing a hospital guideline on pneumonia: a semi-quantitative review. Int J Qual Health Care (2007) 0.77
Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res (2014) 0.77
Stimulating pharmaceutical innovation in the EU. Expert Rev Pharmacoecon Outcomes Res (2011) 0.76
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res (2012) 0.76
Stability of therapeutic albumin solutions used for molecular adsorbent recirculating system-based liver dialysis. Artif Organs (2011) 0.76
The economic burden of COPD exacerbations. COPD (2010) 0.76
Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets? J Aging Soc Policy (2014) 0.75
Prescription of antibiotics in hospitals: prescribers' opinions matter. Lancet Infect Dis (2011) 0.75
Pharmacokinetics of voriconazole during continuous venovenous hemofiltration. Ther Drug Monit (2011) 0.75
Comment: economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother (2011) 0.75
Response to 'Clinical guidelines for the care of adult patients receiving home parenteral nutrition'. Clin Nutr (2012) 0.75
Drug use among persons with Type 2 diabetes mellitus prior to diagnosis in Belgium. Pharmacoepidemiol Drug Saf (2012) 0.75
Increasing the dose of voriconazole compensates for enzyme induction by phenytoin. Br J Clin Pharmacol (2010) 0.75
Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium. Expert Rev Pharmacoecon Outcomes Res (2013) 0.75
Development of quality of care interventions for adult patients on home parenteral nutrition (HPN) with a benign underlying disease using a two-round Delphi approach. Clin Nutr (2012) 0.75
No interaction between valproate and meropenem in a cirrhotic patient. Ann Pharmacother (2011) 0.75
Hurdles that impede economic evaluations of welfare interventions. Expert Rev Pharmacoecon Outcomes Res (2015) 0.75
Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis. Cardiovasc Drugs Ther (2008) 0.75
Reduced length of stay in radical cystectomy patients with oral versus parenteral post-operative nutrition protocol. Int J Clin Pharm (2015) 0.75
Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt. Eur J Clin Pharmacol (2013) 0.75
Analysis of French generic medicines retail market: why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Informing your patients about their medicines: a daily challenge. Int J Pharm Pract (2011) 0.75
Hospital pharmacists versus hospital administrators: a struggle for clinical pharmacy services. Expert Rev Pharmacoecon Outcomes Res (2009) 0.75
Making patient safety a priority: community pharmacy and tools to assure drug supply. Int J Pharm Pract (2010) 0.75
Differentiated information on antidepressants at hospital discharge: a hypothesis-generating study. Int J Pharm Pract (2012) 0.75
Quality of care for cancer patients on home parenteral nutrition: development of key interventions and outcome indicators using a two-round Delphi approach. Support Care Cancer (2012) 0.75
Erratum to: Reduced length of stay in radical cystectomy patients with oral versus parenteral post-operative nutrition protocol. Int J Clin Pharm (2015) 0.75
Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation. J Antimicrob Chemother (2011) 0.75
Estimation and comparison of ostomy appliance costs with tariffs in Belgium. Eur J Health Econ (2006) 0.75
Discharge management for patients in Flemish psychiatric hospitals. J Eval Clin Pract (2010) 0.75